Liang Cheng: Primary Adenocarcinoma of the Urinary Tract and Its Precursors
Liang Cheng, Vice Chair for Translational Research at Warren Alpert Medical School of Brown University, shared an article he and colleagues authored on LinkedIn:
“I’m happy to share our latest review article, “Primary Adenocarcinoma of the Urinary Tract and Its Precursors: Diagnostic Criteria and Classification,” just published in Human Pathology.
Drs. Santa, Akgul, and colleagues provide a comprehensive review of the diagnosis, classification, morphology, immunophenotypic characteristics, and molecular profiles of primary adenocarcinoma, urachal adenocarcinoma, and precursor lesions.
Congratulations to the team – job well done!
Summary
Primary bladder adenocarcinoma represents a rare and diagnostically challenging entity due to its similarity in morphological and immunophenotypic presentation to more common urothelial carcinomas and secondary adenocarcinomas from adjacent organs. Our latest review explores its history, morphology, genetic insights, diagnostic hurdles, and the potential genetic underpinnings that distinguish bladder adenocarcinoma from other neoplasms.
Historically, primary bladder adenocarcinoma was first described in the late 19th century, but its recognition as a distinct pathological entity has been nuanced by its rarity and the overlap with other glandular malignancies in the bladder region. Morphologically, primary adenocarcinoma is characterized by a range of presentations, from enteric types mimicking colorectal adenocarcinomas to rare forms like signet ring cell carcinomas, which pose significant therapeutic and prognostic challenges.
The diagnosis of primary adenocarcinoma is complicated by its immunophenotypic overlap with other adenocarcinomas, making specific markers and genetic profiling essential in its identification and differentiation.
Genetically, primary adenocarcinoma shares several mutations common to colonic adenocarcinomas, such as alterations in KRAS, TP53, and PIK3CA, suggesting a shared molecular pathway that could be explored for targeted therapies. Ongoing research into its molecular characteristics is crucial for identifying specific diagnostic markers and therapeutic targets, which will ultimately improve outcomes for patients with this uncommon malignancy.
Here is the link to the article.”
Authors: Fanni Santa et al.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023